Novartis Has High Hopes For Tasigna And Predicts It Could Outpace Gleevec In CML
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis execs are "pleased" with Tasigna's safety profile in a head-to-head study against the more lucrative CML therapy, Gleevec.
You may also be interested in...
Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval
Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.
Beyond Gleevec: What's Next For Novartis Oncology?
For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug
Beyond Gleevec: What's Next For Novartis Oncology?
For Novartis, the targeted chronic myeloid leukemia drug Gleevec (imatinib) has been the backbone of its oncology portfolio. The drug's launch in 2003 catapulted Novartis into a major oncology player, and with revenues for Gleevec now approaching close to $4 billion in sales annually, the drug has evolved from what was considered to be a niche treatment into Novartis' second top-selling drug